News | April 15, 2025
Biocon Biologics secures market entry date for Yesafili in US
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
The supply of these goods is set to commence within the first quarter of FY26
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
Introduces revolutionary approach to workflow management to enhance operational efficiency and optimize process efficiency
Pregabalin Gel 8% is a novel topical solution for diabetic neuropathic pain
This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202
In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025
Subscribe To Our Newsletter & Stay Updated
